Company: SMNR
Filing Date: 2025-10-21
Form Type: S-1
Source: 0001193125-25-245178
Chunk: 12

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-10-21
Form: S-1
Chunk 12
---
 note dated July 10, 2024, by and between Denali and the Sponsor in the total principal amount of $180,000, which bore no interest and was previously convertible in whole or in part into additional Denali Class A Ordinary Shares at a conversion price of $10.00 per ordinary share. |

| • |     | “Underwriter Shares” means up to 100,000 shares issued to certain underwriters of the initial public offering of Denali upon consummation of the Business Combination as part of a deferred underwriting discount pursuant to that certain Deferred Discount Agreement, dated November 20, 2023, by and among Denali, US Tiger Securities and D. Boral Capital, LLC, and as subsequently amended by the Satisfaction and Discharge Agreements Denali entered into with each of US Tiger Securities and D. Boral Capital, LLC on September 22, 2025 immediately prior to the consummation of the Business Combination. |

| • |     | “US Tiger Securities” or “US Tiger” means US Tiger Securities, Inc. the representative of the underwriters in the IPO. |

| • |     | “VStock” means VStock Transfer, LLC, Denali’s transfer agent. |

| • |     | “Warrants” means together the Private Warrants and the Public Warrants, that entitle the holder thereof to purchase one share of Semnur at an exercise price of $11.50 per share. |

| • |     | “Working Capital Loans” means (i) the Sponsor Convertible Promissory Note and (ii) the Sponsor Extension Convertible Promissory Note. |

6

### PROSPECTUS SUMMARY
This summary highlights selected information that is presented in greater detail elsewhere in this prospectus. Because it is only a summary, it does not contain all of the information you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in this prospectus. Before you decide whether to purchase our securities, you should read this entire prospectus carefully, including the sections of this prospectus titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” You should also carefully read the information in this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.

#### The Company
We are a late-stage clinical biopharmaceutical company focused on developing and